LENZ Therapeutics 披露董事 Scheiner 辭任，董事會縮減至6人並調整審計委員會

lenz-20260630FALSE0001815776Solana BeachCalifornia00018157762026-06-302026-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2026
LENZ THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware001-40532 84-4867570
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

201 Lomas Santa Fe Dr., Suite 300
Solana Beach, California
92075

(Address of principal executive offices)
(Zip code)

(858) 925-7000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.00001 per shareLENZThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he served, effective immediately. Dr. Scheiner’s resignation was not the result of any dispute or disagreement between the Company and Dr. Scheiner on any matter relating to the operations, policies or practices of the Company. Dr. Scheiner has been a valuable member of the Board and the Company expresses its appreciation for Dr. Scheiner’s service and strong work as a member of the Board and the committees on which he served. On June 30, 2026, the Board decreased the size of the Board to six (6) as a result of Dr. Scheiner’s resignation. 
Following the resignation of Dr. Scheiner, on June 30, 2026, the Board appointed Jeff George to its audit committee (the “Audit Committee”). Effective upon such appointment, the members of the Audit Committee are Shelley Thunen, Frederic Guerard, and Jeff George.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LENZ THERAPEUTICS, INC.

Dated: July 2, 2026

By:/s/ Daniel Chevallard
Name:Daniel Chevallard
Title:Chief Financial Officer
(Principal Financial and Accounting Officer)